Can a combination of senolytics with ROCK inhibitors and 5-LOX inhibitors contribute to tissue rejuvenation?

Investigate whether combining senolytics with Rho-associated protein kinase (ROCK) inhibitors and 5-lipoxygenase (5-LOX) inhibitors promotes tissue rejuvenation, and delineate mechanisms and safety profiles.

Background

This question proposes a specific combinatorial therapy targeting senescent cells and signaling pathways.

The authors list it among underrepresented open problems, indicating potential for novel therapeutic exploration.